Endophthalmitis after intravitreal injections

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2119-2126

  Schwartz, Stephen G ^a   Flynn Jr , Harry W ^a   Scott, Ingrid U ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab; Endophthalmitis; Intravitreal; Pegaptanib; Ranibizumab; Triamcinolone; Vascular endothelial growth factor

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BEVACIZUMAB; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; GATIFLOXACIN; GLUCOSE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; ENDOPHTHALMITIS; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; INFLAMMATION; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CLINICAL PROTOCOLS; COAGULASE; DIAGNOSIS, DIFFERENTIAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INJECTIONS; STAPHYLOCOCCUS; TRIAMCINOLONE; VISUAL ACUITY; VITREOUS BODY;

EID: 68949141615     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903081752     Document Type: Review

References (73)

1. Schwartz SG, Flynn HW Jr, Scott IU. Endophthalmitis: classification and current management. Exp Rev Ophthalmol 2007;2(3):385-396
2. Ho J, Loewenstein JI. Endophthalmitis associated with intravitreal injections. Int Ophthalmol Clin 2007;47(2):199-208
3. Stepien KE, Eaton AM, Jafee GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in Spring 2006. Retina 2009;29(2):207-213
4. Jonisch J, Lai JC, Deramo VA, et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol 2008;92(8):1051-1054
5. Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005;36(1):24-29 (Pubitemid 40128598)
6. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138(3):489-492 (Pubitemid 39208586)
7. Sharma MC, Lai WW, Shapiro MJ. Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 2004;23(4):398-399 (Pubitemid 38544059)
8. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121(9):1279-1282 (Pubitemid 37128405)
9. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87(8):972-974
10. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin® ). Br J Ophthalmol 2008. [Epub ahead of print]
11. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24(3):326-363 (Pubitemid 351733229)
12. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246(5):779-781
13. Available from: http://www.nelm.nhs.uk/ en/NeLM-Area/News/2009--- February/23/ Reports-of-eye-inflammation-and-sterileendophthalmitis- following-intravitrealbevacizumab- Avastin/ [Accessed 4 June 2009]
14. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91(9):1122-1124 (Pubitemid 47344879)
15. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141(3):579-580 (Pubitemid 43265975)
16. Chen SD, Lochhead J, Patel CK. Diffuse intraocular dispersion of triamcinolone particles as a cause of sterile endophthalmitis. Arch Ophthalmol 2004;122(11):1733 (Pubitemid 39473432)
17. Marticorena J, Gomez-Ulla F, Romano MR, Luna I. Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone. Graefes Arch Clin Exp Ophthalmol 2007;245(9):1403-1404 (Pubitemid 47278681)
18. Amato JE, Lee DH, Santos BA, Akduman L. Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflam 2005;13(2-3):245-247 (Pubitemid 41711298)
19. Yoon SJ, Rhee DY, Marx JL, et al. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol 2009;147(6):1031-1036
20. Roth DB, Flynn HW. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008;146(3):346-347
21. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23(5):686-691 (Pubitemid 37315056)
22. Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121(9):1279-1282 (Pubitemid 37128405)
23. Mahajan VB, Folk JC, Boldt HC. A head-tilt test for hypopyon after intravitreal triamcinolone. Retina 2009;29(4):560-561
24. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-2816 (Pubitemid 40051904)
25. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;133:633-642
26. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 1444 (Pubitemid 44511558)
27. Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431 (Pubitemid 44511557)
28. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthlamol 2008;145(5):862-874
29. Bhavsar AR, Ip MS, Glassman AR, et al. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144(3):454-456
30. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009. [Epub ahead of print]
31. Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009. In press
32. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28(10):1395-1399
33. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349 (Pubitemid 44702055)
34. Jonas JB, Spandau UH, Schlictenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008;22(4);590-1
35. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116(6):1225
36. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye 2007;21(3):317-320 (Pubitemid 46358790)
37. Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28(4):564-567
38. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796 (Pubitemid 37330020)
39. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145(5):879-882
40. Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-1077 (Pubitemid 41159300)
41. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthlamol 2008;246(1):81-87
42. Miller JJ, Scott IU, Flynn HW, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139(6):983-987
43. Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina 2008;28(1):138-142
44. Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002;33(5):373-378
45. Scott IU, Flynn HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27(1):10-12 (Pubitemid 46095824)
46. Lad EM, Moshfeghi DM. Minimizing the risk of endophthalmitis following intravitreal injections. Compr Ophthalmol Update 2006;7(6):277-284 (Pubitemid 46579460)
47. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(Suppl 5):S3-19
48. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991;98:1769-1775
49. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol 2007;27(5):307-312 (Pubitemid 47377475)
50. de Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008;28(6):877-883
51. Ciulla TA, Starr MB, Basket S. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence-based update. Ophthlamology 2002;109:13-26
52. Scott IU, Flynn HW. The role of topical antibiotic prophylaxis for intravitreal injections. Arch Ophthlamol 2007;125(7):974-976 (Pubitemid 47076442)
53. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006;142:721-725
54. Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application. Ophthalmologe 2007;104(11):952-957
55. Miller D, Flynn PM, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006;124:479-483
56. Bhavsar AR. A consecutive series of 1,000 intravitreous injections without topical antibiotic prophylaxis. Invest Ophthalmol Vis Sci 2008;49:e-Abstract 5617
57. Javey G, Kapoor N, Rosenfeld PJ. Elimination of post-injection topical antibiotics after intravitreal injections. Invest Ophthalmol Vis Sci 2009;50: e-Abstract 5016
58. Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol 2007;144(1):50-54
59. Alexandrou TJ, Hariprasad SM, Benevento J, et al. Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointment. Trans Am Ophthalmol Soc 2006;104:196-201 (Pubitemid 46495081)
60. Aggio FB, Farah ME, de Melo GB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007;21(3):408-409 (Pubitemid 46358806)
61. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-1496
62. Han DP, Wisniewsi SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17 (Pubitemid 26230889)
63. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2004;121:345-350 (Pubitemid 36298116)
64. Park-Wyllie LY, Juurlink DM, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361
65. Smiddy WE, Smiddy RJ, Ba'Arath B, et al. Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 2005;25:751-758
66. Tetsuju S, Iida T, Kaneko H, Saito M. Cytomegalovirus retinitis after intravitreal triamcinolone acetonide in an immunocompetent patient. Jpn J Ophthalmol 2008;52(5):414-416
67. Park YS, Byeon SH. Cytomegalovirus retinitis after intravitreous triamcionlone injection in a patient with central retinal vein occlusion. Korean J Ophthalmol 2008;22(2);143-4
68. Delyfer MN, Rougier MB, Hubschman JP, et al. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol Scand 2007;85(6):681-683
69. Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 2005;140(6):1141-1143 (Pubitemid 41821313)
70. Aggermann T, Stolba U, Brunner S, Binder S. Endophthalmitis with retinal necrosis following intravitreal triamcionlone acetonide injection. Ophthalmologica 2006;220(2):131-133 (Pubitemid 43289457)
71. Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-273 (Pubitemid 36184044)
72. Alkuraya HS, Al-Kharashi AS, Alharthi E, Chaudry IA. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 2008. [Epub ahead of print]
73. Murray RJ, Aravena-Roman M, Kampfer P. Endophthalmitis due to Williamsia muralis. J Med Microbiol 2007;56:1410-1412